Tekla Healthcare Investors (HQH) Fair Value 2026

HQH · — ·

By CirclFi Research Team · Data from SEC EDGAR, FRED & GDELT

Quality Score

2.2 /10

32 fundamental signals · 8 models active

Value Trap Risk

— (—/100)

Quick Summary — As of 2026-07-15, Tekla Healthcare Investors (HQH) trades at $21.03, approximately 240% above CirclFi’s Bayesian DCF fair value of $6.19. QOC: 2.2/10. 8/13 models active.

Key Facts

Ticker
HQH
Price
$21.03
Quality Score
2.2/10
Value Trap Risk
—/100
Models Active
8/13
Last Updated
Strength: CUCE Ensemble suggests +86.0% upside with 0% confidence
Risk: Below-average Quality Score of 2.2/10 signals weak fundamentals

Is Tekla Healthcare Investors (HQH) Undervalued or Overvalued in 2026?

According to CirclFi’s 8-model valuation engine, Tekla Healthcare Investors (HQH) appears fairly valued as of : the median of 8 independent fair value estimates is $21.72, within 3.3% of the current price of $21.03. Estimates range from $0.30 to $46.64. HQH scores 2.2/10 on fundamental quality and —/100 on value-trap risk.

This verdict compares price to intrinsic value only — it is not a buy or sell rating. For the decision case (bull vs bear arguments, risk factors, peers), read Should You Buy Tekla Healthcare Investors Stock in 2026? →

Valuation Matrix

8 Intrinsic Value Models vs. Current Price ($21.03)

Core Models (Unlocked)
Model Fair Value Upside
Bayesian DCF
Low Conviction
 $6.19 -70.6%
CUCE Ensemble
Low Conviction
 $39.11 +86.0%
First Chicago
Low Conviction
 $23.82 +13.3%
PWERM
Low Conviction
 $19.62 -6.7%

Unlock the Full Matrix

Access 4 additional models including ML-RIV, Dynamic NAV, and more.

$1.30 / day

Billed monthly ($39/mo) or annually ($299/yr)

Unlock All 8 Models →

Cancel anytime · No contracts · Instant access

What Is Tekla Healthcare Investors (HQH) Worth in 2026?

According to the CirclFi Deep Alpha Valuation Engine, Tekla Healthcare Investors's intrinsic value is estimated at a composite $21.19, showing conflicting signals at the current price of $21.03. While the average implied return is +0.8%, model disagreement is elevated with a gap of +220.4% between the most bullish and bearish estimates. The most optimistic model, ML-RIV, places fair value at $46.64 (+121.8%), while Regime Cross — the most conservative — estimates $0.30 (-98.6%). This +220.4% gap reflects genuine analytical uncertainty about Tekla Healthcare Investors's intrinsic worth.

What Do the Models Say About HQH?

8 of 13 models are currently active for HQH. Of these, 4 models suggest upside while 4 models suggest overvaluation. The Bayesian DCF estimates HQH's intrinsic value at $6.19, implying -70.6% downside from the current price. See which stocks rank higher →

How Does HQH Rank in —?

HQH operates in the — sector. CirclFi's QOC score of 2.2/10 evaluates 32 fundamental signals. A score of 2.2 signals below-average fundamentals.

Tekla Healthcare Investors operates in a competitive landscape where fundamental quality metrics are key differentiators for long-term value creation.

Is HQH a Value Trap?

The Value Trap algorithm is not active for HQH. The score cross-references apparent undervaluation against fundamental deterioration signals. Browse lowest value-trap stocks →

Multi-Model Methodology

8 of 13 models are active for Tekla Healthcare Investors. Moderate coverage provides meaningful perspective. Each model applies a fundamentally different valuation philosophy. See the complete methodology →

According to the CirclFi 32-factor quality framework, Tekla Healthcare Investors's fundamental quality profile registers 2.2/10. This concerning score captures the company's profitability depth, growth consistency, balance sheet resilience, and shareholder return track record.

The gap between the most bullish and bearish model spans +220.4% — demonstrating why single-model analysis is dangerous. Browse all stocks with 13-model coverage →

Data Sources & Confidence

Every HQH valuation is built from SEC EDGAR XBRL filings — 700+ standardized financial tags. Macroeconomic context from FRED calibrates discount rates, while GDELT news sentiment feeds into our Sentiment SOTP model. All pipelines run daily. Read the complete data methodology →

Across HQH's 8 active models, average confidence is 2%. Lower confidence may reflect limited history or high volatility.

CirclFi's output is a research starting point, not a buy/sell signal. All data updates daily. Read the full methodology →

This analysis is produced by the CirclFi Valuation Engine using quantitative models applied to SEC EDGAR filings, public market feeds, and FRED macroeconomic indicators. It is not financial advice.

Read the full investment analysis: Should You Buy Tekla Healthcare Investors Stock in 2026? →

Bull case, bear case, risk factors & peer comparison — updated daily

Which Similar — Stocks Should You Also Analyze?

8 related — stocks with 13-model coverage

PSECProspect Capital CorporationQOC 8.4SCMStellus Capital Investment CorpQOC 7.8FDUSFidus Investment CorporationQOC 7.6HTGCHercules Capital, Inc.QOC 7.6GLADGladstone Capital CorporationQOC 7.4TPVGTriplePoint Venture Growth BDC QOC 7.3OXSQOxford Square Capital Corp.QOC 7.2GBDCGolub Capital BDC, Inc.QOC 7.2

Read investment analysis: PSEC · SCM · FDUS · HTGC · GLAD

Frequently Asked Questions About Tekla Healthcare Investors

What is Tekla Healthcare Investors's intrinsic value in 2026?

Based on CirclFi's 13-model analysis, Tekla Healthcare Investors (HQH) has multiple fair value estimates. The Bayesian DCF model runs 10,000 Monte Carlo simulations with jump-diffusion to estimate intrinsic value at $6.19. The Quality of Company score is 2.2/10 across 32 fundamental signals. All models use SEC EDGAR filings updated daily. See our methodology page for how each model works.

Is HQH overvalued or undervalued right now?

At $21.03, 4 of 8 active models suggest HQH may be undervalued, while 4 indicate potential overvaluation. The median of all 8 fair value estimates is $21.72, within 3.3% of the current price of $21.03 — a consensus view that HQH is fairly valued. The assessment depends on which methodology best fits Tekla Healthcare Investors's business model in —.

What does a Quality of Company score of 2.2 mean for HQH?

Tekla Healthcare Investors's QOC of 2.2/10 reflects 32 fundamental signals: profitability margins, revenue growth consistency, balance sheet leverage, free cash flow generation, and capital allocation efficiency. Scores below 5 flag potential fundamental weaknesses requiring careful analysis.

How many valuation models does CirclFi run on HQH?

CirclFi analyzes HQH with 13 institutional-grade models daily: Bayesian DCF (Monte Carlo + jump-diffusion), EPV (Greenwald zero-growth), EROIC Spread (McKinsey reinvestment), First Chicago (3-scenario), Markov DDM (regime-switching), ML-RIV (machine learning residual income), Dynamic NAV (asset-based), PWERM (option-theoretic), Regime Cross-Sectional (relative), Sentiment SOTP (hybrid), CUCE Ensemble (meta-model), FTNN Topology (neural network), and RCMH-DCF (conditional regime). Currently 8 of 13 are active for this stock. Read the full methodology →

Is HQH a value trap in 2026?

CirclFi's Value Trap algorithm does not have sufficient data for HQH at this time. Browse stocks by value-trap risk →

Cite this analysis — “According to CirclFi’s 8-model valuation engine, Tekla Healthcare Investors (HQH) has a median fair value of $21.72 — within 3.3% of the current price of $21.03 — as of 2026-07-15.” Source: circlfi.com/stock/HQH/ · Methodology

You’ve done the research. Don’t stop at half the picture.

Stop collecting opinions. Let 8 mathematical frameworks give you clarity on HQH.

Unlock All 8 Fair Values — $39/mo

Cancel anytime · Less than a cup of coffee · Instant access